ATE348589T1 - Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten - Google Patents

Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten

Info

Publication number
ATE348589T1
ATE348589T1 AT98946738T AT98946738T ATE348589T1 AT E348589 T1 ATE348589 T1 AT E348589T1 AT 98946738 T AT98946738 T AT 98946738T AT 98946738 T AT98946738 T AT 98946738T AT E348589 T1 ATE348589 T1 AT E348589T1
Authority
AT
Austria
Prior art keywords
adrenomedullin
amylin
analogues
treatment
cartilage defects
Prior art date
Application number
AT98946738T
Other languages
English (en)
Inventor
Ian Reginald Reid
Jillian Cornish
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of ATE348589T1 publication Critical patent/ATE348589T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/34—Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage
AT98946738T 1997-09-26 1998-09-25 Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten ATE348589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ32885397 1997-09-26

Publications (1)

Publication Number Publication Date
ATE348589T1 true ATE348589T1 (de) 2007-01-15

Family

ID=19926460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946738T ATE348589T1 (de) 1997-09-26 1998-09-25 Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten

Country Status (7)

Country Link
US (2) US6869926B1 (de)
EP (1) EP1027027B1 (de)
JP (1) JP2001524454A (de)
AT (1) ATE348589T1 (de)
AU (1) AU9369098A (de)
DE (1) DE69836689D1 (de)
WO (1) WO1999016406A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440421B1 (en) * 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
EP1027027B1 (de) 1997-09-26 2006-12-20 Auckland Uniservices Limited Verwendung von Amylin, Adrenomedullin und deren Analoga zur Behandlung von Knorpeldefekten
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
EP1878436B1 (de) * 2005-03-07 2014-07-23 National Cerebral and Cardiovascular Center Verfahren zur regeneration oder reparatur von geschädigtem gewebe mit adrenomedulin
ES2754478T3 (es) * 2015-03-12 2020-04-17 Fund Rioja Salud Uso de un inhibidor de la adrenomedulina para la fabricación de un medicamento útil en la prevención y tratamiento de enfermedades que reducen la densidad ósea
US10464983B2 (en) * 2015-05-13 2019-11-05 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5922677A (en) * 1994-07-13 1999-07-13 Auckland Uniservices Limited Therapeutic method and compounds of use therein
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
WO1997007214A1 (en) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
US6440421B1 (en) * 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
EP1027027B1 (de) * 1997-09-26 2006-12-20 Auckland Uniservices Limited Verwendung von Amylin, Adrenomedullin und deren Analoga zur Behandlung von Knorpeldefekten
US9602269B2 (en) * 2013-05-13 2017-03-21 Acer Incorporated Dynamic time division duplexing method and apparatuses using the same

Also Published As

Publication number Publication date
JP2001524454A (ja) 2001-12-04
US7208469B2 (en) 2007-04-24
AU9369098A (en) 1999-04-23
EP1027027A2 (de) 2000-08-16
US20050171007A1 (en) 2005-08-04
WO1999016406A3 (en) 1999-07-08
DE69836689D1 (de) 2007-02-01
WO1999016406A2 (en) 1999-04-08
US6869926B1 (en) 2005-03-22
EP1027027B1 (de) 2006-12-20
EP1027027A4 (de) 2004-10-27

Similar Documents

Publication Publication Date Title
US4535775A (en) Method for treatment of non-union bone fractures by non-invasive electrical stimulation
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE433324T1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
ATE390932T1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
ATE219678T1 (de) Wirkstoff zur stimulation von hartem gewebe
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69731540D1 (de) Behandlung von diarrhoe
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE362781T1 (de) System zur behandlung von bewegungs- fehlfunktionen
TR199901173T2 (xx) Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
DE60320770D1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE260107T1 (de) Debromhymenialdisin und verwandte verbindungen zur behandlung von osteoarthritis
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE348589T1 (de) Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE312175T1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties